ebmt diagnostic criteria for tma post-allosct and the role of complement activation
Published 2 months ago • 96 plays • Length 2:20Download video MP4
Download video MP3
Similar videos
-
2:12
the diagnosis and management of ta-tma in pediatric patients
-
4:52
the collaboration of the ebmt and isct for the development and monitoring of atmps and soho
-
1:52
targeting the lectin pathway in hsct-tma
-
1:08
the progress of the ebmt & key ongoing projects
-
3:58
complement inhibition for the treatment of ta-tma
-
1:43
highlights from ebmt 2022
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
![antigen-specific t cells [webinar]](https://i.ytimg.com/vi/WJrFVY-E1pc/mqdefault.jpg)
54:19
antigen-specific t cells [webinar]
-
3:18
emr - laboratory panel
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
1:27
current diagnostic modalities for the identification of ptld
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
0:59
the importance of the ebmt-eha european car t-cell meeting 2024
-
0:38
the functional role of cd4- and cd8-expressing t-cells in aml
-
1:53
the detection and management of mnts following bcma-directed car-t therapy
-
1:17
overview of hsct and gvhd at ebmt
-
1:07
key advancements in the treatment of bpdcn from ebmt 2024
-
1:33
zamtocabtagene autoleucel for the treatment of patients with r/r dlbcl
-
2:42
the importance of the ebmt/jacie benchmarking program for hsct outcomes
-
0:59
identifying molecular markers for the prediction of icaht in patients receiving car t-cell therapy
-
1:26
cellular therapy: a key part of ebmt 2017